Renal impairment considerations in type 2 diabetes prescribing

Click here to access the module

This module is hosted externally

Pharmacy Modules

CHAPTER 1

Hypoglycaemia and type 2 diabetes

Click here to access the module

This module is hosted externally

CHAPTER 2

Renal function decline and type 2 diabetes

Click here to access the module

This module is hosted externally

eLearning module: Renal function decline and type 2 diabetes

CHAPTER 3

Type 2 diabetes in a frail older person

Click here to access the module

This module is hosted externally

View related resources

Know more

Know more

Know more

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:

monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

PC-GB-110531 V2 | July 2025

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.

eLearning Modules